Hetero Labs submits ANDA220421 for Vemagal with standard review priority
Hetero Labs Limited has submitted ANDA220421 for Vemagal, currently under standard review.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Neurology / Generic Drug
Company: Hetero Labs Limited
Asset: Vemagal
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Hetero Labs Limited
Asset
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
The submission of ANDA220421 by Hetero Labs for Vemagal marks a significant entry into the generic market, which could disrupt pricing and market share dynamics for existing branded products. Portfolio teams need to closely monitor this development to strategize accordingly.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review progress and any potential approval timelines for ANDA220421.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.